Novartis Canada extends Health Equity Initiative effort, fueling innovation and impact for second year Français
MONTREAL, May 14, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the launch of the second edition Health Equity Initiative. Aimed at promoting equitable healthcare for Canadians by addressing health disparities, Novartis Canada will award $500,000 to non-profit projects focused on improving health equity and addressing the unique healthcare challenges faced by underserved and marginalized populations.
According to the World Health Organization, health equity is achieved when everyone can attain their full potential for health and well-being. i However, despite having a universal healthcare system, Canada ranks third to last with respect to equity in healthcare access and experience among nine peer countries, highlighting persistent challenges faced by underserved communities. ii
The 2025 Health Equity Initiative aims to address Canada's existing healthcare access inequity by supporting individuals and organizations that are fully immersed in their communities, understand their unique needs, and are dedicated to advancing fair access to healthcare. By empowering these agents of change, Novartis seeks to inspire broader community engagement and action to improve healthcare outcomes.
Sustaining the momentum from the inaugural Health Equity Initiative in 2024, Novartis will be awarding additional grants to support Canadian non-profit and/or charitable organizations that are pioneering innovative solutions towards equitable healthcare.
"We are incredibly proud to continue our commitment to supporting health equity in Canada by launching the second year of this Initiative," said Mark Vineis, Country President, Novartis Canada. "All Canadians deserve equitable access to healthcare and Novartis believes in the power of supporting sustainable, grassroots projects that help advance health equity for underserved communities."
In total, more than 130 applications for funding were received in the Initiative's first year. The 2024 winners were selected through a thorough evaluation process designed in collaboration with Equity Mobilizing Partnerships in Community (EMPaCT), each exemplifying the spirit and impact of the Initiative through their innovative approaches to addressing and improving health equity:
Black Physicians of Canada: By creating a national database of Black physicians across Canada, this project is to tackling health disparities and improving access to culturally sensitive care, ensuring that Black patients receive health services that acknowledge and respect their unique needs. The development of a Black health digital hub further enhances connectivity and resource sharing among healthcare providers and patients.
Foundations for Social Change: This project addresses the health equity challenges faced by those transitioning out of homelessness and extreme poverty in Vancouver by implementing a comprehensive support system – including mental health services, healthcare navigation support and direct cash transfers – to empower individuals with the tools and resources needed to improve health outcomes.
Fort Severn First Nation: The northernmost community in Ontario, this project focuses on bridging the healthcare access gap for First Nations communities. By establishing a team of community health coordinators known as Payukotayno Meno ya win, the initiative ensures timely diagnosis and treatment, as well as access to preventative care. These efforts promote greater engagement between families and the healthcare system, fostering trust and improving overall health outcomes within the community.
"The Health Equity Initiative's 2024 winners have set a powerful precedent, showcasing the impact of a community-based focus on innovation and collaboration," says Vineis. "Novartis Canada recognizes the importance of supporting community organizations and is committed to supporting all future winners in their missions to drive meaningful action."
How to apply for funding
Canadian non-profit and/charitable organizations that are passionate about advancing health equity and committed to creating a more inclusive healthcare system are encouraged to learn more and apply for funding by visiting www.novartis.com/ca-en/esg/health-equity-initiative.
The deadline for applications is 11:59 p.m. PT on June 16, 2025
About Novartis
Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit www.novartis.ca.
SOURCE Novartis Pharmaceuticals Canada Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Canada Health Infoway Launches AI Scribe Program: Enrollment Now Open for Primary Care Clinicians Français
TORONTO, June 10, 2025 /CNW/ - Canada Health Infoway ("Infoway") is proud to announce the official launch of the AI Scribe Program, a national initiative designed to reduce administrative burden, improve documentation workflows, and support more connected, patient-centered care through the power of artificial intelligence. Enrollment is now open for eligible primary care clinicians across Canada. The program provides up to 10,000 fully funded, one-year licenses for AI-powered documentation tools to support eligible primary care clinicians in delivering more efficient and focused care. Eligible clinicians include family physicians, nurse practitioners, registered nurses in remote communities, and pediatricians providing longitudinal, community-based care. These innovative tools help automate time-consuming tasks such as clinical note-taking, appointment preparation, and follow-up documentation, giving clinicians more time to focus on what matters most: delivering high-quality, patient-centered care. "The launch of the AI Scribe Program represents a powerful step forward for Canada's healthcare system," said Abhi Kalra, Executive Vice President of Connected Care at Canada Health Infoway. "By enabling clinicians to access AI-powered tools that reduce documentation time, we're not only improving their day-to-day experience, but we're also laying the groundwork for better data quality, improved patient outcomes, and a more connected care journey. AI scribes are just the beginning, and getting this right is key to building a stronger, smarter, and more sustainable health system for the future." Eligible primary care clinicians can now begin the registration process by visiting Infoway's national AI Scribe Program website, selecting their province or territory to determine eligibility and access to the tools available in their area. Program implementation is delivered in close collaboration with provinces and territories, with availability, access, and execution varying by jurisdiction. This ensures the program supports the realities of care delivery across Canada while maintaining alignment with national goals. Announced in May 2025, a pre-qualified group of trusted vendors is available through the program, selected through a rigorous national procurement process based on their ability to meet national standards and unique regional needs, support secure data sharing, meet clinical practice requirements, and align with the Shared Pan-Canadian Interoperability Roadmap. The AI Scribe Program supports not only the introduction of a transformative digital solution, but it also signals a broader shift in how Canada equips clinicians with the technology they need to reduce administrative burden, streamline documentation, and deliver more connected, sustainable care. If you are a primary care clinician interested in learning more or participating, visit: A Pathway for AI in Clinical Workflows The AI Scribe Program is the first step in a broader effort to integrate similar technologies into Canada's healthcare system. The AI Scribe Program introduces a maturity model that supports a structured framework for advancing interoperability, progressively enhancing AI scribes' integration with digital health systems. It defines a clear vision for improving data quality and interoperability by aligning AI scribe adoption with pan-Canadian standards, ensuring these tools seamlessly connect within the broader health ecosystem. Future phases aim to explore scalability, incorporate discrete data elements coded to national terminologies, and AI-assisted decision support, ensuring AI-powered tools remain trusted, secure, and effective for Canadian clinicians now and into the future. To learn more about the national AI Scribe Program, please visit us here. If you have questions, please contact us at: [email protected] About Canada Health Infoway At Canada Health Infoway (Infoway) we believe a more connected and collaborative system is a healthier system, and one that leads to better health outcomes for all Canadians. By leveraging digital technologies and innovations, we're working with governments, healthcare organizations, clinicians, and patients to advance connected care across the country. This improves care coordination, empowers patients to have a more active role in managing their health, and equips care providers with information and insights to support better care both at the point of care and throughout their patients' health journey. Most importantly, it modernizes our health care system towards a future with patient-centered care at its heart. We're an independent, not-for-profit organization funded by the federal government and accountable to our Board of Directors and Members of the Corporation (Canada's 14 federal, provincial and territorial deputy ministers of health). Infoway is led by a team of seasoned professionals who are specialists in their respective fields, including health care, administration, information technology and privacy. Visit us online at MEDIA INQUIRIES Haley Armstrong Senior Director, Communications and Public Relations Canada Health Infoway 519-939-9549
2 hours ago
Dentists praise Canadian Dental Care program, but also express concern over influx of new patients
A northern Ontario dentist says the Canadian Dental Care Plan has generally been positive, but he worries it could cause issues meeting higher demand for dental care over the long term. In June, eligible Canadians between the ages of 18 and 64 can start receiving dental coverage under the plan. Dr. Thomas Detert, a dental surgeon based in Blind River, said the dental plan is bringing in patients who haven't been to a dentist's office in years. Some of them are like over 10 or 15 years because when they retired, they lost their benefits, he said. In some cases, Detert said those patients had good oral hygiene habits and didn't need significant dental care. But in other cases, they put off going to the dentist until they were in serious pain, and needed significant work. While the program has benefited those people, Detert said there's a risk demand for dental care could outstrip the ability of dentists and other oral health professionals to meet it. Much like our socialized medicine in Canada, without proper prevention and education, the demand [has] outstripped any amount of supply that can be thrown at it. And that's what I'm afraid of for socialized dentistry, he said. Around 3.6 million Canadians have been approved by the Canadian Dental Care Plan and around 1.9 million people received care through the plan, as of April. Dr. Jerry Smith, a dentist from Thunder Bay, Ont., and the past president of the Ontario Dental Association, said another 4.5 million Canadians could qualify for the plan with the cohort of people between the ages of 18 and 64. Smith agreed the plan has been positive for people who might not be able to afford dental care otherwise. But he worries a shortage of dental hygienists and assistants will make it challenging for dentists to properly serve an influx of new patients. In Ontario alone, there is a shortage of about 3,400 dental assistants and about 5,500 dental hygienists, he said, quoting figures from a 2022 analysis conducted by the Ontario Dental Association. The Canadian Dental Association estimates that with the increase in patients from the Canadian Dental Care Plan, Canada will need an additional 2,300 dental assistants and over 1,500 dental hygienists in 2025. The numbers from the Ontario Dental Association reference its estimates for the total shortage in the province. In a statement to CBC News Marg Harrington, the CEO of the Ontario Dental Hygienists' Association, said that while some dental practices might struggle attracting dental hygienists, the narrative of a provincewide shortage is inaccurate. The fact is there are more dental hygienists in Ontario than ever before, Harrington said. Registration data from the College of Dental Hygienists of Ontario show a steady increase over the past few years in the number of dental hygienists registered in Ontario. Harrington said that research published last month in the BMC Oral Health journal showed that Ontario had 97 registered dental hygienists per 100,000 population in 2023, which is substantially higher than other provinces. Jonathan Migneault (new window) · CBC News
Cision Canada
2 hours ago
- Cision Canada
Curadev Expands Strategic Collaboration for CRD3874-SI Through MSK Therapeutics Accelerator Program
BOSTON, June 10, 2025 /CNW/ -- Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK), a world-leading cancer research and treatment institution, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of Curadev's small-molecule allosteric Stimulator of Interferon Genes (STING) agonist, CRD3874-SI, to be delivered systemically to patients with advanced/metastatic cancer. The collaboration builds on the ongoing Phase 1a/b dose escalation and expansion clinical trial (NCT06021626) currently underway at MSK for sarcoma and Merkel cell carcinoma patients, and aims to explore the potential of CRD3874-SI in treating additional types of cancer. Through the MSK Therapeutics Accelerator program, MSK will provide Curadev with expertise and institutional resources, including medical, clinical, and regulatory advice, to further the development of CRD3874-SI. This expanded collaboration marks a significant milestone in translating promising STING pathway research into broader clinical application and will be overseen by William Tap, MD, Chief of the Sarcoma Medical Oncology Service at MSK, and Ciara Kelly, MBBCh BAO, Interim Clinical Director of MSK's Sarcoma Oncology Service. Dr. William Tap said, "MSK and its Division of Solid Tumors are excited to co-develop CRD3874-SI, a novel first-in-class allosteric STING agonist, with Curadev. CRD3874-SI has demonstrated an encouraging safety and efficacy profile in a first-in-human study at MSK. CRD3874-SI is moving forward into multiple solid-tumor expansion cohorts, guided by disease specific experts and the support and structure of the MSK Accelerator Program, which is designed to enhance and expedite the development of novel compounds across malignancies. CRD3874-SI has the potential to offer patients a new treatment option with continued innovation and exploration of the benefits of immunotherapy in cancer care." Dr. Arjun Surya, Co-founder and CEO of Curadev, added, "We are encouraged by the early readouts with CRD3874-SI systemic monotherapy from our ongoing clinical trial in patients with treatment refractory cancers at MSK and are honored by the opportunity to deepen our collaboration through the MSK Therapeutics Accelerator program. The research and development collaboration between oncologists at MSK and the inventors of CRD3874-SI at Curadev could become a role model for advancing bench to bedside medicines. MSK's historic leadership position in the development of cancer immunotherapy and the exemplary dedication of the oncologists we work with is inspiring and make it an ideal partner in Curadev's effort to investigate the therapeutic potential of its systemically administered allosteric STING agonist in patients with advanced/metastatic cancer." About Curadev Curadev is a clinical-stage biotechnology company dedicated to discovering and developing novel small-molecule therapeutics for treating intractable diseases. Curadev has built an impressive portfolio of discovery research programs using a target-centric approach, innovative screening schemes, and traditional wet-lab chemistry and pharmacology, resulting in patent-protected drug candidates that modulate next-generation drug targets. Curadev Pharma, Inc., the US-based clinical development subsidiary founded in 2021, is currently leading the Phase1/2 trials of STING agonist assets under a US FDA-approved IND application. For more information, visit MSK's Therapeutics Accelerator program is a strategic partnership program between MSK and biotechnology companies to advance novel cancer therapeutics through all stages of drug development. The program brings together innovative healthcare companies with MSK's community of clinical and scientific experts to establish groundbreaking collaborations that can have a tangible impact on the treatment or management of cancer.
